Aptevo Therapeutics (APVO) to Release Earnings on Wednesday

Aptevo Therapeutics (NASDAQ:APVO) is anticipated to release its results before the market opens on Wednesday, April 1st. Analysts expect Aptevo Therapeutics to post earnings of ($8.10) per share for the quarter.

Aptevo Therapeutics Trading Down 6.0%

APVO stock opened at $4.22 on Wednesday. The firm has a market cap of $4.22 million, a PE ratio of 0.00 and a beta of 1.44. Aptevo Therapeutics has a 1 year low of $3.95 and a 1 year high of $1,299.60. The company has a fifty day simple moving average of $6.81 and a 200 day simple moving average of $17.35.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Virtu Financial LLC acquired a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned 1.16% of Aptevo Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 8.06% of the company’s stock.

Wall Street Analysts Forecast Growth

APVO has been the topic of several recent research reports. Weiss Ratings restated a “sell (e)” rating on shares of Aptevo Therapeutics in a report on Monday, December 29th. Wall Street Zen lowered Aptevo Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold”.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.